1,409 reports of this reaction
4.0% of all EXTENDED PHENYTOIN SODIUM reports
#2 most reported adverse reaction
SEIZURE is the #2 most commonly reported adverse reaction for EXTENDED PHENYTOIN SODIUM, manufactured by Viatris Specialty LLC. There are 1,409 FDA adverse event reports linking EXTENDED PHENYTOIN SODIUM to SEIZURE. This represents approximately 4.0% of all 34,830 adverse event reports for this drug.
Patients taking EXTENDED PHENYTOIN SODIUM who experience seizure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEIZURE is moderately reported among EXTENDED PHENYTOIN SODIUM users, representing a notable but not dominant share of adverse events.
In addition to seizure, the following adverse reactions have been reported for EXTENDED PHENYTOIN SODIUM:
The following drugs have also been linked to seizure in FDA adverse event reports:
SEIZURE has been reported as an adverse event in 1,409 FDA reports for EXTENDED PHENYTOIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEIZURE accounts for approximately 4.0% of all adverse event reports for EXTENDED PHENYTOIN SODIUM, making it one of the most commonly reported side effect.
If you experience seizure while taking EXTENDED PHENYTOIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.